Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Non Operating Income: 2014-2024

Historic Non Operating Income for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to -$69.5 million.

  • ImmunityBio's Non Operating Income fell 112.38% to -$11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.9 million, marking a year-over-year increase of 61.38%. This contributed to the annual value of -$69.5 million for FY2024, which is 68.66% up from last year.
  • Per ImmunityBio's latest filing, its Non Operating Income stood at -$69.5 million for FY2024, which was up 68.66% from -$221.6 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Non Operating Income ranged from a high of -$5.2 million in FY2020 and a low of -$221.6 million during FY2023.
  • Its 3-year average for Non Operating Income is -$119.0 million, with a median of -$69.5 million in 2024.
  • In the last 5 years, ImmunityBio's Non Operating Income crashed by 279.57% in 2021 and then surged by 68.66% in 2024.
  • Over the past 5 years, ImmunityBio's Non Operating Income (Yearly) stood at -$5.2 million in 2020, then plummeted by 279.57% to -$19.6 million in 2021, then plummeted by 237.38% to -$66.0 million in 2022, then tumbled by 235.88% to -$221.6 million in 2023, then spiked by 68.66% to -$69.5 million in 2024.